Breast Cancer

I have read the CME Disclosures

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through Joint Sponsorship of New York Medical College and the Angiogenesis Foundation. New York Medical College is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION
New York Medical College designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits�. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Credit will be awarded provided this activity is used and completed according to instructions and a score of 70% or better is achieved. A certificate of credit will be issued to those who successfully complete the examination.

RELEASE AND EXPIRATION
Date of original release: March 28, 2013
Date of expiration: March 27, 2014
CME Course Code: 2013BRCA

TARGET AUDIENCE
Practicing oncologists and primary care physicians in the U.S., researchers and medical students

HEALTHCARE GAP
In the United States alone, more than 232,340 new cases of metastatic breast cancer will be diagnosed in 2013, and an estimated 39,620 will die from this disease. Breast cancer is the most common cancer among women in the United States, other than skin cancer. It is the second leading cause of cancer death in women, after lung cancer. The chance of a woman having invasive breast cancer some time during her life is a little less than 1 in 8. The chance of dying from breast cancer is about 1 in 35.

Three critical needs have been identified by the Angiogenesis Foundation in regards to breast cancer. There is a large amount of new information emerging on breast cancer therapies and clinicians do not have enough time to adequately review all of this important information in this rapidly expanding field. Clinicians are not educating patients about the side effects of antiangiogenic therapy and referring patients to specialists to optimize management of side effects and increasing patient outcomes. There are many clinical trials out there researching several new targeted therapies, providing clinicians with this updated information will help increase enrollment in these clinical trials and can lead to an increase in the number of treatment options with fewer side effects.

PROGRAM LEARNING OBJECTIVES
At the completion of this activity, participants should be able to:

  • Describe the role of tumor angiogenesis as both a disease mechanism and therapeutic target in breast cancer.
  • Explain how antiangiogenic therapies may be integrated into current breast cancer treatment regimens, including front-line, second-line, maintenance, and adjuvant therapy settings.
  • Discuss clinical efficacy and safety data from recent studies on antiangiogenic therapies for breast cancer.
  • Describe common safety concerns of antiangiogenic cancer therapy and their management.
  • Explain strategies for addressing progressive disease, including the use of combination antiangiogenic treatment or new therapy targets under investigation.

ACTIVITY GOAL
This activity is designed to address the following ABMS / IOM competencies:
Patient Care and Medical Knowledge

METHOD OF PARTICIPATION
There are no fees for participating in and receiving credit for this online educational activity. The participant should, in order, read the objectives and faculty disclosures, review the educational content, answer the multiple-choice post-test and complete the evaluation. This program is available in PDF format accessible from the Angiogenesis Foundation's website (http://www.angio.org) in the CME section. A print version is also available; for more information contact outreach@angio.org. After reviewing the material, CME credits are available through the Angiogenesis Foundation's website (http://www.cmeonline.org) by selecting the name of the program (registration required). Course code: 2013BRCA

ACKNOWLEDGEMENT OF SUPPORT
This activity is supported by an educational grant from Novartis.

COURSE FACULTY
William Li, MD
Dartmouth Medical College

DISCLOSURE
New York Medical College asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. New York Medical College has procedures to resolve apparent conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

William W. Li, M.D.
President, the Angiogenesis Foundation, Editor-in-Chief
Dr. Li has nothing to disclose with regard to commercial interests.

Erin Grothey, M.S.
Medical writer.
Medical Writer has no relevant financial relationships to disclose. Erin Grothey's spouse received grant/research support from Genentech and Eli Lilly and Company.

Kathy Kavanaugh
Margaret Astrologo
Planning Committee, New York Medical College
Members of the planning committee have no relevant financial relationships to disclose.

All New York Medical College and Angiogenesis Foundation employees in control of content have indicated that they have no relevant financial relationships to disclose.

DISCUSSION OF UNLABELLED USE
This CME activity contains discussion of published and/or investigational use of: AZD4547, bevacizumab, everolimus, foretinib, MK-2206, ornatuzumab, pazopanib, ramucirumab, sorafenib, sunitinib.

TOPICS AND EDUCATIONAL CONTENT
Antiangiogenic therapy for breast cancer:

  • Clinical Progress for Antiangiogenic Therapy for Breast Cancer
  • Antiangiogenic Agents in Clinical Development for Breast Cancer
  • Metronomic Chemotherapy
  • Subpopulation Analysis and Biomarkers
  • Side Effects of Antiangiogenic Therapy for Breast Cancer
  • Future directions


SYSTEM REQUIREMENTS
This educational program is available in PDF format. To view and print PDF files, you must have Adobe Reader installed on your computer. Most computers already have this software installed. If yours does not, you can download Adobe Reader free from the Adobe Web site: http://www.adobe.com.

For questions about this program, please contact the Angiogenesis Foundation at 617-401-2779 or outreach@angio.org.